ASTRO: No Survival Benefit for Adding EBT to Brachytherapy

Share this content:
ASTRO: No Survival Benefit for Adding EBT to Brachytherapy
ASTRO: No Survival Benefit for Adding EBT to Brachytherapy

WEDNESDAY, Sept. 28, 2016 (HealthDay News) -- Among men with intermediate-risk prostate cancer, the addition of external beam therapy (EBT) to transperineal interstitial permanent brachytherapy (B) does not improve five-year progression-free survival, according to a study presented at the annual meeting of the American Society for Radiation Oncology, held from Sept. 25 to 28 in Boston.

Bradley R. Prestidge, M.D., from the DePaul Medical Center in Norfolk, Va., and colleagues randomized men with prostate cancer to receive 45 Gy partial pelvis EBT + B or B alone. Five hundred eighty-eight men were randomized (287 EBT + B eligible and 292 B eligible); patients were followed for a median of 6.7 years.

The researchers found that five-year progression-free survival was 85 percent for the EBT + B arm and 86 percent for the B arm at the fifth interim analysis of 443 patients with five years of follow-up (hazard ratio, 1.02; futility P = 0.0006). The Data Monitoring Committee recommended early release for the initial reporting of the primary end point. Similar acute overall ≥ grade 3 toxicity was seen (8 percent for EBT + B and B). Overall ≥ grade 3 late toxicity was 12 and 7 percent for EBT + B and B, respectively.

"These findings suggest that many men with intermediate risk prostate cancer can be well managed with seed implant alone and do not require the addition of external beam radiation," Prestidge said in a statement.

Press Release
More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA Approves First Drug for Rare Form of Rickets

FDA Approves First Drug for Rare Form of ...

Crysvita approved for adults and children ages 1 year and older with x-linked hypophosphatemia

High FGF-23 Linked to Recurrent Cardiac Events After ACS

High FGF-23 Linked to Recurrent Cardiac Events After ...

FGF-23 in top quartile independently linked to greater risk of CV death, heart failure hospitalization

Medical Cannabis Not Recommended for Sleep Apnea

Medical Cannabis Not Recommended for Sleep Apnea

American Academy of Sleep Medicine says evidence insufficient to recommend cannabis for apnea

is free, fast, and customized just for you!

Already a member?

Sign In Now »